Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARCT-2303 + influenza vaccine
- Development stage
- Unknown
- Lead developer
- Arcturus Therapeutics
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
ARCT-2303 + influenza vaccine refers to the concomitant administration of ARCT-2303, a self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, with seasonal quadrivalent influenza vaccines. Developed by Arcturus Therapeutics in collaboration with CSL, ARCT-2303 (marketed as KOSTAIVE) encodes the spike glycoprotein of the SARS-CoV-2 Omicron XBB.1.5 subvariant. The combination was evaluated in a Phase 3 clinical trial to assess the safety and immunogenicity of simultaneous vaccination. The study utilized age-appropriate influenza vaccines, including non-adjuvanted quadrivalent vaccines for adults aged 18-64 and adjuvanted quadrivalent vaccines for adults aged 65 and older. This co-administration strategy is intended to streamline immunization schedules and provide simultaneous protection against both COVID-19 and seasonal influenza.
- Brand names
- KOSTAIVE
- Other names
- ARCT-2303 and quadrivalent influenza vaccineARCT2303 and quadrivalent influenza vaccineARCT 2303 and quadrivalent influenza vaccinesa-mRNA COVID-19 vaccine + influenza vaccine
02
Targets
HA (Hemagglutinin)SARS-CoV-2 spike
Beyond the preview
Go deeper on ARCT-2303 + influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARCT-2303 + influenza vaccine.